期刊文献+

RNA干扰相关肿瘤治疗药物的研究进展 被引量:3

原文传递
导出
摘要 研发针对肿瘤细胞表面抗原的靶向药物和针对肿瘤细胞异常信号通路的抑制剂,是目前肿瘤治疗药物研发的主要目标。但由于药物研发周期长和治疗效果差等方面的原因,制约了肿瘤靶向药物的发展。RNA干扰(RNA interference,RNAi)的发现,为人们提供了相对快速且具有革命性的肿瘤药物设计途径。从利用双链RNA(doublestrandRNA,dsRNA)选择性下调新杆状线虫基因表达到RNAi在哺乳动物中的研究,短短的10年时间,已经有多种RNAi相关药物进入临床试验阶段,其中包括对肿瘤的靶向治疗药物。虽然临床试验结果表明,RNAi药物具有一定的治疗作用,但是RNAi肿瘤靶向药物进入临床应用还需要进一步的研究与开发。一。
出处 《中华肿瘤杂志》 CAS CSCD 北大核心 2012年第11期801-804,共4页 Chinese Journal of Oncology
基金 国家重大新药创制科技专项(2009ZX09103) 国家自然科学基金(30870921、81170632) 科技部国际科技合作与交流专项(2012DFAl1070) 教育部博士点基金(20100001110047)
关键词 RNA干扰 抗肿瘤药 小分子RNA 小干扰RNA RNA interference Antineoplastic agents MicroRNAs Small interfering RNA
  • 相关文献

参考文献2

二级参考文献11

  • 1张敬杰,欧阳涛,万文徽,邓国仁.乳腺癌患者外周血浆中游离的肿瘤相关DNA检测及其临床价值[J].中华肿瘤杂志,2007,29(8):609-613. 被引量:6
  • 2Ma L, de Roquancourt A, Bertheau P, et al. Expression of amphiregulin and epidermal growth factor receptor in human breast cancer: analysis of autocriny and paracriny. J Pathol, 2001, 194:412-418.
  • 3Ma L, Gauville C, Berthois Y, et al. Role of epidermal-growth-factor receptor in tumor progression in transformed human mammary epithelial cells. Int J Cancer, 1998, 78:112-119.
  • 4Ma L, Gauville C, Berthois Y, et al. Antisense expression for amphiregulin suppresses tumorigenicity of a transformed human breast epithelial cell line. Oncogene, 1999, 18:6513-6520.
  • 5Wellmann S, Taube T, Paal K, et al. Specific reverse transcription-PCR quantification of vascular endothelial growth factor (VEGF) splice variants by LightCycler technology. Clin Chem, 2001, 47:654-660.
  • 6Berquin IM, Dziubinski ML, Nolan GP, et al. A functional screen for genes inducing epidermal growth factor autonomy of human mammary epithelial cells confirms the role of amphiregulin. Oncogene, 2001, 20:4019-4028.
  • 7Kato T, Kameoka S, Kimura T, et al. The combination of angiogenesis and blood vessel invasion as a prognostic indicator in primary breast cancer. Br J Cancer, 2003, 88:1900-1908.
  • 8Gille J, Swerlick RA, Caughman SW. Transforming growth factor-alpha-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation. EMBO J, 1997, 16:750-759.
  • 9Xi Chen,Yi Ba,Lijia Ma,Xing Cai,Yuan Yin,Kehui Wang,Jig ang Guo,Yujing Zhang,Jiangning Chen,Xing Guo,Qibin Li,Xiaoying Li,Wenjing Wang,Yan Zhang,Jin Wang,Xueyuan Jiang,Yang Xiang,Chen Xu,Pingping Zheng,Juanbin Zhang,Ruiqiang Li,Hongjie Zhang,Xiaobin Shang,Ting Gong,Guang Ning,Jun Wang,Ke Zen,Junfeng Zhang,Chen-Yu Zhang.Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases[J].Cell Research,2008,18(10):997-1006. 被引量:983
  • 10张春智,康春生,浦佩玉,王广秀,贾志凡,张安玲,韩磊,许鹏.反义microRNA-221与反义microRNA-222抑制人脑胶质瘤细胞的体外与体内生长[J].中华肿瘤杂志,2009,31(10):721-726. 被引量:8

共引文献9

同被引文献26

  • 1KANEKO H, FUKAO T, KASAHARA K, YAMADA T, KONDO N. Augmented cell death with Bloom syndrome helicase deficiency[J]. Mol Med Rep, 2011, 4: 607-609.
  • 2RAMACHANDRAN P V, IGNAEIMUTHU S. RNA interference——a silent but an efficient therapeutic tool[J]. Appl Biochem Biotechnol, 2013, 169: 1774-1789.
  • 3JIN X, SUN T, ZHAO C, ZHENG Y, ZHANG Y, CAI W, et al. Strand antagonism in RNAi: an explanation of differences in potency between intracellularly expressed siRNA and shRNA[J]. Nucleic Acids Res, 2012, 40: 1797-1806.
  • 4SELKIRK M E, HUANG S C, KNOX D P, BRITTON C. The development of RNA interference (RNAi) in gastrointestinal nematodes[J]. Parasitology, 2012, 139: 605-612.
  • 5PENG A, WANG L, FISHER L A. Greatwall and Polo-like kinase 1 coordinate to promote checkpoint recovery[J]. J Biol Chem, 2011, 286: 28996-29004.
  • 6GONDI C S, RAO J S. Concepts in vivo siRNA delivery for cancer therapy[J]. J Cell Physiol, 2009, 220: 285-291.
  • 7KIM D H, ROSSI J J. Strategies for silencing human disease using RNA interference[J]. Nat Rev Genet, 2007, 8: 173-184.
  • 8ANTHONY R V, CANTLON J D. Ribonucleic acid interference:a new approach to the in vivo study of gene function[J]. J Anim Sci, 2007, 85(13 Suppl): E18-E19.
  • 9TUSCHL T. Expanding small RNA interference[J]. Nat Biotechnol, 2002, 20: 446-448.
  • 10DE MUYT A, JESSOP L, KOLAR E, SOURIRAJAN A, CHEN J, DAYANI Y, et al. BLM helicase ortholog Sgs1 is a central regulator of meiotic recombination intermediate metabolism[J]. Mol Cell, 2012, 46: 43-53.

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部